Is the gold rush in immunotherapy trials good? – MedCity News
MedCity News |
Is the gold rush in immunotherapy trials good?
MedCity News Although the concept of immunotherapy has been around for more than a century, it only gained prominence as a method of targeted cancer therapy in the early 2000s. In 2015, Merck's Keytruda® (pembrolizumab), a checkpoint inhibitor drug, made … |
